A study on the safety, tolerability, and effectiveness of the new drug LAD106 in healthy volunteers.

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523328-31-00

Enrollment

Registered

2026-02-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory diseases

None listed

Sex/Gender

All

Age

18 Years to 64 Years

None listed

Source: EU CTIS · Data processed: Feb 7, 2026